$zfgn
"met all primary objectives"

"favorable safety and tolerability profile..no treatment-related serious adverse events and no cv safety signals.."

higher dose data in "early 2019"

synergistic preclinical data for 1061 + liraglutide (~victoza $)

ev&lt;$150m